Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel

• Status: Recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Pediatric patients 6 years and older undergoing minor pediatric urologic surgery

• Patients who are otherwise eligible to receive routine care following minor urologic surgery

Exclusion Criteria:

• Contraindication to receiving local anesthetics (i.e. pre-existing cardiac, renal, hepatic dysfunction)

• Pediatric patients younger than 6 years of age

• Pediatric patients with a history of pain syndromes or are unable to tolerate opiate medication

• Unwilling to participate in 48 hours and 10-14 day follow-up phone calls